Phase II clinical trial - Sein Adjuvant

BREASTIMMUNE03 / CA209-9XD

Sein Adjuvant

Essai clinique fermé

Public cible

Adulte

Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (BreastImmune03)

Description de l'essai

To evaluate the clinical benefit of a post-operative adjuvant therapy combining radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitabine in Triple Negative Breast Cancer (TNBC) patients with residual disease after neoadjuvant chemotherapy

Liens utiles

Lien de l'essai

JEAN-YVES PIERGA

Investigateur principal

JEAN-YVES PIERGA

Investigateur principal